Shares of Kezar Life Sciences (NASDAQ:KZR) fell 11% Thursday after the company said its board of directors had unanimously rejected an unsolicited takeover offer from Concentra Biosciences and ...

Orru leamen nu ahte don geavahat boares neahttalohkki. Vai beasat oaidnit buot mii Yras lea, de rávvet du ođasmahttit iežat neahttalohkki. JavaScript ii oro leamen doaimmas du neahttalohkkis. Jos ...

It looks like you're using an old browser. To access all of the content on Yr, we recommend that you update your browser. It looks like JavaScript is disabled in your browser. To access all the ...

After hours: October 28 at 7:59 PM EDT Loading Chart for KZR ...

An iconic Maine property is now available one mile from the boat launch on Kezar Lake. This family compound is the former location of Melder's German Restaurant and Brathaus, made famous by patron ...

With Kezar Life Sciences’ lupus plans up in the air while the company investigates patient deaths, Concentra Biosciences has spied an opportunity to scoop up another troubled biotech.

SOUTH SAN FRANCISCO, Calif., October 10, 2024--(BUSINESS WIRE)--Kezar Life Sciences, Inc. ("Kezar" or the "Company") (Nasdaq: KZR), a clinical-stage biotechnology ...

Credit: Sebastian Kaulitzki / Shutterstock. US-based biopharmaceutical company Kezar Life Sciences has suspended subject enrolment and patient dosing in the Phase II PALIZADE trial of zetomipzomib for ...